Page last updated: 2024-08-26

yttrium radioisotopes and Vomiting

yttrium radioisotopes has been researched along with Vomiting in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Fusco, F; Gibbs, P; Gray, AM; Love, S; Moschandreas, J; Sharma, RA; Van Hazel, G; Virdee, PS; Wasan, HS; Wolstenholme, J1
Devlin, PM; Khan, AJ; Siddiqi, NH1
Atassi, B; Benson, AB; Gates, VL; Gupta, R; Lewandowski, RJ; Memon, K; Miller, FH; Mulcahy, MF; Newman, S; Nikolaidis, P; Omary, RA; Riaz, A; Ryu, RK; Salem, R; Sato, KT; Yaghmai, V1
Bartolomei, M; Bodei, L; Caracciolo, M; Chinol, M; Cremonesi, M; Grana, C; Mäcke, HR; Paganelli, G; Rocca, P; Zoboli, S1
Barone, R; Bouterfa, H; Carlier, P; Chen, T; de Camps, J; Jamar, F; Krenning, EP; Kvols, LK; Labar, D; Mathieu, I; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Walrand, S1

Trials

3 trial(s) available for yttrium radioisotopes and Vomiting

ArticleYear
Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-global randomised trials of selective internal radiotherapy for metastatic colorectal cancer.
    International journal of cancer, 2020, 08-15, Volume: 147, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colorectal Neoplasms; Fatigue; Female; Humans; Liver Neoplasms; Male; Middle Aged; Nausea; Quality of Life; Surveys and Questionnaires; Vomiting; Yttrium Radioisotopes

2020
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study.
    European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:2

    Topics: Adult; Aged; Amino Acids; Biomarkers, Tumor; Blood Platelets; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Hemoglobins; Humans; Kidney; Lymphocytes; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Octreotide; Radiation-Protective Agents; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Renal Insufficiency; Vomiting; Yttrium Radioisotopes

2003
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.
    European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:4

    Topics: Adult; Aged; Amino Acids; Arginine; Cohort Studies; Cross-Over Studies; Dizziness; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney; Lysine; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Dosage; Radiation Injuries; Radiation-Protective Agents; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Vomiting; Yttrium Radioisotopes

2003

Other Studies

2 other study(ies) available for yttrium radioisotopes and Vomiting

ArticleYear
Palonosetron--a single-dose antiemetic adjunct for hepatic artery radioembolization: a feasibility study.
    Cardiovascular and interventional radiology, 2009, Volume: 32, Issue:1

    Topics: Embolization, Therapeutic; Feasibility Studies; Female; Hepatic Artery; Humans; Isoquinolines; Liver Neoplasms; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Treatment Outcome; Vomiting; Yttrium Radioisotopes

2009
Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes.
    International journal of radiation oncology, biology, physics, 2012, Jul-01, Volume: 83, Issue:3

    Topics: Abdominal Pain; Aged; Analysis of Variance; Diarrhea; Embolization, Therapeutic; Fatigue; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Nausea; Neuroendocrine Tumors; Retrospective Studies; Survival Rate; Treatment Outcome; Vomiting; Weight Loss; Yttrium Radioisotopes

2012